AADI News and Press, Aadi Bioscience Inc. From 03/01/22

LOS ANGELES, March 01, 2022 (GLOBE NEWSWIRE) -- Aadi Bioscience, Inc. (“Aadi”) (Nasdaq:AADI), a biopharmaceutical company focusing on precision therapies for genetically-defined cancers with alterations in mTOR pathway genes, today announced that Founder, Chief Executive Offic...

Aadi Bioscience (NASDAQ:AADI) launched its first proprietary product, Fyarro to treat a rare form of cancer. In November 2021, the FDA approved Fyarro (sirolimus protein-bound particles for injectable suspension) (albumin-bound) for intravenous use to treat patients with locally adv...

– FYARRO™ added to NCCN ® Guidelines as the only preferred mTOR inhibitor to treat malignant PEComa – – PRECISION-1 tumor agnostic study for TSC1 or TSC2 alterations is open for enrollment – LOS ANGELES, Feb. 23, 20...

LOS ANGELES, Jan. 04, 2022 (GLOBE NEWSWIRE) -- Aadi Bioscience, Inc. (“Aadi”), a biopharmaceutical company focusing on precision therapies for genetically-defined cancers with alterations in mTOR pathway genes, today announced that Founder, Chief Executive Officer and Presiden...

Aadi Bioscience receives FDA approval of Fyarro for treatment of patients with PEComa. Fyarro (ABI-009) can be expanded upon in two specific gene pathways known as TSC1 and TSC2; this could bring access to thousands of new patients. Further expansion of ABI-009 can be achieved wit...

Pasithea Therapeutics (NASDAQ:KTTA) +172% adds Esketamine nasal spray to its clinic offerings in the U.K. Petros Pharmaceuticals (NASDAQ:PTPI) +99%. iSpecimen ISPC +99% is set to extend rally after contract win for COVID-19 research Qualigen Therapeutics (NASDAQ:QLGN) +72%. Aad...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Good morning, investors! We’re getting right back to the grind today with a dive into the biggest pre-market stock movers for Tuesday. Source: Shutterstock News moving stocks early this morning include earnin...

Aadi Bioscience (NASDAQ:AADI) is trading ~48.3% higher in the pre-market after announcing the FDA approval of FYARRO as an intravenous treatment for adults with an ultra-rare form of cancer called PEComa. The FDA decision allows the use of FYARRO (sirolimus protein-bound particles f...

FYARRO is the first and only approved therapy for adults for the treatment of malignant PEComa, an ultra-rare and aggressive form of sarcoma with a strong female predominance FYARRO launch planned for Q1 2022; Investor call to be held today at 8:30 am ET LOS ANGELES,...

In an Expanded Access Program, advanced malignant PEComa patients who previously progressed on other mTOR inhibitors showed a 25% partial response rate and 63% clinical benefit rate when treated with nab-sirolimus; the subset of patients with TSC1 or TSC2 alterations showed a 44% re...